Sarah Booth, PhD
Dr. Booth is interim director of the Jean Mayer USDA Human Nutrition Research Center on Aging, as well as a senior scientist and director of the HNRCA’s Vitamin K Laboratory. She also is a professor in the Biochemical and Molecular Nutrition program at the Friedman School. Booth’s research interests include Vitamin K food composition, dietary assessment, nutritional assessment, and bioavailability.
Elizabeth Byrnes, PhD
The overarching theme of Dr. Byrnes’s current research is identifying mechanisms by which various experiences lead to long-term changes in neural and endocrine systems. Moreover, she is interested in how sex influences the impact of particular experiences on both brain and behavior. Currently she has three main areas of focus. The first involves studies examining the transgenerational consequences of adolescent drug exposure (opiates and cannabinoids) in female rats with an emphasis on multigenerational patterns of substance abuse. The second involves studies examining the effects of both sex and experience on the neural regulation of the stress axis, particularly as it relates to modifications in anxiety and depressive-like behaviors. The third involves studies examining the effects of prenatal substance use (opiates and cocaine) on both the female and her offspring.
John Coffin, PhD
Dr. Coffin’s research interests revolve around obtaining a better understanding of the interaction of retroviruses with their host cells and organisms. He uses simple retroviruses (avian and murine viruses) to elucidate the nature of the retrovirus-receptor interaction; the mechanism and specificity of integration of viral DNA into host DNA; control of viral gene expression; mechanism of retroviral genetic variation; and evolution of the host-virus relationship, as revealed by the fossil record provided by endogenous proviruses found in the normal DNA of all vertebrates and many other species.
Jonathan Davis, MD
Dr. Davis is Vice-Chair of Pediatrics and Chief of Newborn Medicine at the Floating Hospital for Children at Tufts Medical Center and Professor of Pediatrics at Tufts University School of Medicine. His research has focused on breathing problems in newborn infants, causes of newborn brain injury, and neonatal drug development. He has authored over 150 manuscripts and book chapters and received numerous grant awards from the National Institutes of Health, the FDA, the March of Dimes, the American Lung Association and many others. Dr. Davis has lectured worldwide including the Vatican Children’s Hospital in Rome, the Pasteur Research Institute in Paris, and the National Academy of Sciences in Washington. Dr. Davis has conducted the basic science and animal studies to support human trials of exogenous surfactant, human recombinant antioxidants, human recombinant anti-inflammatory agents (rhCC10), and many other drugs and devices in newborn infants and has been intimately involved in trial design, data collection, data analyses, and peer-reviewed publications. He is currently funded by NIH and FDA to develop better biomarkers and outcome measures for clinical trials and new and existing therapeutics to improve neonatal outcome. Dr. Davis is Chair of the Neonatal Advisory Committee in the Office of Pediatric Therapeutics at FDA and was recently elected to the Leadership Council of the American Pediatric Society. He has been actively involved in the Clinical and Translational Science Award Program and the BPCA Prioritization Committee at NIH. These positions permit him to work closely with NIH, FDA, academic leaders, and Industry to promote the development of important pediatric therapeutics.
Elazer Edelman, MD, PhD
Dr. Edelman is the Thomas D. and Virginia W. Cabot Professor of Health Sciences and Technology at MIT, Professor of Medicine at Harvard Medical School, and a coronary care unit cardiologist at the Brigham and Women’s Hospital in Boston. He and his laboratory have pioneered basic findings in vascular biology and the development and assessment of biotechnology. Dr. Edelman directs the Harvard-MIT Biomedical Engineering Center (BMEC), dedicated to applying the rigors of the physical sciences to elucidate fundamental biologic processes and mechanisms of disease. BMEC programs span a wide range of disciplines, with its resources made available to investigators from MIT and Harvard.
Dr. Edelman received Bachelor of Science degrees in Bioelectrical Engineering and in Applied Biology from MIT in 1978, a Masters of Science degree in Electrical Engineering and Computer Sciences from MIT in 1979, a degree in medicine from Harvard Medical School in 1983 and a PhD in Medical Engineering and Medical Physics from MIT in 1984. His graduate thesis work, under the direction of Prof. Robert Langer, defined the mathematics of regulated and controlled drug delivery systems. After internal medicine training and clinical fellowship in Cardiovascular Medicine at the BWH he spent six years as a research fellow in the Department of Pathology at Harvard Medical School with Prof. Morris J. Karnovsky working on the biology of vascular repair.
John Essigmann, PhD
Dr. Essigmann is the William R. (1956) and Betsy P. Leitch Professor in Residence of Chemistry in the MIT Department of Chemistry and Professor of Toxicology and Biological Engineering in the MIT Department of Biological Engineering. He was the Associate Head of the Department of Chemistry until 2012, responsible for graduate and undergraduate education, and since that time he has been the Director of the MIT Center for Environmental Health Sciences.
Professor Essigmann was brought up in Medford, MA, a suburb of Boston and is a lifelong resident of the Boston area. He went to Northeastern University for his undergraduate degree in chemistry and subsequently earned his Ph.D. from MIT with Professor Gerald Wogan, a pioneer in the field of toxicology.
Roger Fielding, PhD
Dr. Fielding is Director and Senior Scientist of the Nutrition, Exercise Physiology, and Sarcopenia (NEPS) Laboratory at the Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University. He is also Professor of Nutrition at the Friedman School of Nutrition Science and Policy, Professor of Medicine at Tufts University School of Medicine, and Lecturer of Physical Medicine and Rehabilitation at Harvard Medical School. Currently, he also serves as the Associate Director of the Boston Claude D. Pepper Older Americans Independence Center.
James Fox, DVM
Dr. Fox obtained his Master of Science degree in Medical Microbiology at Stanford University and a Doctor in Veterinary Medicine at the Colorado State University, Fort Collins. Dr. Fox is an Adjunct Professor at Tufts University School of Veterinary Medicine and the University of Pennsylvania, School of Veterinary Medicine. He is a Diplomate and a past president of the American College of Laboratory Animal Medicine, past president of the Massachusetts Society of Medical Research, past chairman of AAALAC Council, and past chairman of the NCCR/NIH Comparative Medicine Study Section. He also is an elected fellow of the Infectious Disease Society of America. In 2004 Professor Fox was elected to the Institute of Medicine of the National Academy of Sciences.
Karen M. Freund, MD, MPH
Dr. Freund is the KL2 Career Development Award Program Director. Her translational research focus is in addressing health disparities through implementation research to translate known therapies into underserved populations. Her current and recent NIH funding addresses patient navigation to reduce cancer disparities. She and her colleagues have developed a database from their RCT on patient navigation, with over 10,000 subjects with abnormal cancer screening , and 2,000 with a cancer diagnosis. The database also includes an extensive qualitative database. Dr. Freund’s research also includes comparative effectiveness research to assess the impact of insurance reform. She has extensive experience at using electronic medical records for secondary administrative database analysis.
Her current R01 examines the factors that predict academic faculty success in minority and women faculty, working with a national longitudinal database of over 1,000 medical school faculty members over 15 years.
Jonathan Garlick, DDS, PhD
Recent advances in stem cell biology have created new opportunities to study human developmental and disease processes as they occur in cells and tissues. Dr. Garlick’s laboratory is developing experimental approaches to derive mesenchymal and epithelial cell types from induced pluripotent stem cells (iPSC). His ultimate goal is to use these cells for personalized therapies for regeneration and repair of diseased or damaged tissues and organs. He continues to develop and apply novel 3D, human bioengineered tissues that provide powerful platforms that closely mimic the form and function of human tissues and organs. Dr. Garlick views 3D tissues harboring a broad spectrum of stem cells as a powerful translational platform that we leverage to test the function of iPSC-derived cells in an in vivo-like microenvironment and are allowing him to move his field from studying “disease in a dish” to studying “disease in a tissue.”
Constance Horgan, ScD
Constance M. Horgan, ScD is a Professor at the Heller School for Social Policy and Management at Brandeis University and is the founding Director of its Institute for Behavioral Health. From 2007-2013, she served as the Associate Dean for Research. Dr. Horgan received her doctorate in health policy and management from the Johns Hopkins University and masters in demography from Georgetown University. Dr. Horgan’s expertise is in health policy analysis and services research. Specifically, her research is focused on how alcohol, drug and mental health services are financed, organized, and delivered in the public and private sectors and what approaches can be used to improve the quality and effectiveness of the delivery system. She directed the Alcohol and Drug Services Study funded by the Substance Abuse and Mental Health Services Administration (SAMHSA) in the mid-1990s which provided a national perspective on what the substance abuse treatment system looked like in terms of organization, financing, cost and characteristics and post-treatment status of the clients it served. Dr. Horgan has led studies for a range of federal agencies (Agency for Healthcare Research and Quality (AHRQ), National Institute of Mental Health (NIMH), National Institute on Alcohol Abuse and Alcoholism (NIAAA), the National Institute on Drug Abuse (NIDA), SAMHSA; state governments; and foundations, including the Robert Wood Johnson Foundation.
Linden Hu, MD
Dr. Hu is currently Vice Chairman for Faculty Development in the Department of Medicine as well as Associate Chief for Research in the Division of Geographic Medicine and Infectious disease. In both of these roles, he has been responsible for mentoring post-doctoral fellows and young faculty in their research careers. In addition, he has served as either director or associate director of a T32 training grant for the last 10 years. As such, he is very familiar with the challenges faced by our young faculty and post-doctoral fellows and is well acquainted with the resources available to help them progress with their careers. Over the last four years, over 75% of the junior faculty members who have participated in programs he has developed for the Department have received NIH funding, including four R01s and multiple K awards.
Dr. Hu’s research has focused on Lyme disease, where he has been involved in both basic laboratory and clinical research for almost 20 years. He has participated in the development of both human and animal vaccines for Lyme disease as well as the development of new diagnostic tests. At the bench, his laboratory is interested in host-pathogen interactions between Borrelia burgdorferi and the innate immune system. Three members of his laboratory have received individual F31 or F32 awards.
Gordon Huggins, MD
For Dr. Huggins, the primary goal of his laboratory is to make discoveries relevant to human diseases for the purpose of understanding the biology of human development and disease that, in addition to providing greater insight into mechanisms of disease, may also translate to biomarkers or therapies. To achieve this goal, whenever possible his laboratory seeks to make primary discoveries by studying human DNA and/or tissues. Genes or pathways identified through discovery work based upon human samples then serve as the basis for traditional hypothesis-oriented research in animal and cellular model systems. Dr. Huggins has been privileged to mentor graduate students and post-doctoral fellows. In addition to his work in Tufts Medical Center, he is a faculty member at Tufts Graduate School of Biomedical Sciences Genetics program and Cell, Molecular and Developmental Biology Program.
Iris Jaffe, MD, PhD
Dr. Jaffe is an Associate Professor of Medicine at Tufts University School of Medicine, Director of the MCRI, Co-Director of the MCRC, and a staff physician in the Division of Cardiology at Tufts Medical Center. She received her M.D. degree and a Ph.D. in Molecular Biology from the University of Pennsylvania in Philadelphia and completed her Internal Medicine training at the Massachusetts General Hospital followed by Cardiology fellowship training at the Brigham and Women’s Hospital, both in Boston.
The primary focus of the Jaffe lab is to understand the molecular mechanisms underlying common vascular disorders including hypertension, vascular remodeling, and atherosclerosis with specific emphasis on the role of the renin-angiotensin-aldosterone system. The Jaffe laboratory demonstrated the presence of functional mineralocorticoid receptors (MR) in human vascular cells and is studying the role of vascular MR in cardiovascular function and disease. The lab uses in vitro molecular techniques in vascular cells, genome wide “omics” analyses of cardiovascular tissues, whole vessels studies of vascular function, and in vivo tissue-specific transgenic mouse models to study vascular structure, function, and responses to injury and atherogenic stimuli to identify the molecular mechanisms of vascular disease and identify novel treatment targets.
David M. Kent, MD, CM, MSc
Dr. Kent is Director of the Clinical and Translational Science (CTS) MS/PhD Graduate Program of the Tufts Clinical and Translational Science Institute (CTSI) and the Tufts Graduate School of Biomedical Sciences. Within the CTS program, Dr. Kent teaches Study Design, Predictive Modeling and Introduction to Clinical Care Research. He is also a Clinical Investigator in the Institute for Clinical Research and Health Policy Studies (ICRHPS), Tufts Medical Center, an attending physician in Internal Medicine at Tufts Medical Center and an Associate Professor of Medicine at Tufts University School of Medicine. His principal research interest is in the clinical importance of outcome-risk and treatment-effect heterogeneity in clinical trials and his research has focused primarily on cardiovascular and cerebrovascular disease. Among other projects, he is currently PI of the NIH/NINDS-sponsored R01 Risk of Paradoxical Embolism (RoPE) Study, a multinational study to determine how to select from patients presenting with cryptogenic stroke those likely to benefit from closure of a patent foramen ovale, a related R21 examining different antithrombotic strategies on this population, and PI on a PCORI methods grant empirically evaluating a framework to examine heterogeneity of treatment effect in RCTs. Finally, Dr. Kent is the recipient of a U-Award to examine the expected value of individualized care across a range of interventions, collaborating with investigators at CEVR and Erasmus University (in Rotterdam). He is highly committed to mentoring the next generation of clinical researchers and has had numerous mentees, who themselves have been productive researchers.
Charlotte Kuperwasser, PhD
Dr. Kuperwasser has been working in the field of mammary gland development, breast cancer and stromal-epithelial cell biology for over a decade. Her current research focuses on studying the pathogenesis of breast cancer with an emphasis on molecular mechanisms that regulate normal and cancer stem cells, differentiation, and stromal-epithelial interactions. Dr. Kuperwasser has created several novel mouse and xenograft models to successfully model as well as recreate normal and neoplastic human breast tissues in mice. These studies have demonstrated the importance of the human breast stromal cells in the normal development of human breast epithelium as well as in the promotion of pre-neoplastic and neoplastic growth. The Kuperwasser laboratory was one of the first to demonstrate that initiating mutations in key oncogenes or tumor suppressors can act to disrupt the differentiation programs of breast progenitor populations, thereby influencing the type of tumor that will develop. Recently, the laboratory reported that initiating mutations in BRCA1 can act prior to evidence of breast cancer incidence to disrupt the lineage commitment programs of breast progenitor populations, thereby influencing the epigenetic state of the progenitor cells and dictating which type of tumor will develop. In addition, Dr. Kuperwasser and her laboratory have been enumerating the cellular and functional activities of various cell types within human and mouse mammary tissues and mapped them to the cellular origins of breast cancers. Recent findings indicate that adult human breast tissues contain uncommitted epidermal cells or cells which are prone to loss of mammary specification. Dr. Kuperwasser and her laboratory have the expertise and experience combined with a continued successful track record in the field ensures a continued record of successful and productive research in an area of high clinical and translational relevance to cancer.
Dr. Kuperwasser has extensive mentoring and career development training expertise having trained 13 predoctoral students, four medical students, three oncology fellows and 10 postdoctoral fellows. Her mentoring demonstrates a track record in promoting the careers of underrepresented minority trainees and faculty, with local and national awards for mentoring. Her current R01 examines the factors that predict academic faculty success in minority and women faculty, and provides insight into best practices for mentoring.
Dr. Lichtenstein’s primary area of research is focused on assessing the interplay between diet and cardiovascular disease risk at a basic, clinical and population level, primarily focused on older women and men. She has had the opportunity to mentor predoctoral students and postdoctoral fellows, either in a primary or secondary capacity. As a result of these efforts in 2008 she was awarded the ‘Mentor of Women Award’ by the American Heart Association’s Council on Atherosclerosis, Thrombosis and Vascular Biology. I currently serve as a co-mentor for the Nutrition, Physical Activity and Metabolism Early Career Committee for the American Heart Association.
Peter Lindenauer, MD
Dr. Lindenauer is Director of the Center for Quality of Care Research at Baystate Medical Center and Associate Professor of Medicine at Tufts University School of Medicine. His translational research focus is defining optimal clinical strategies through observational comparative effectiveness research, and improving healthcare delivery using implementation research methods to design, implement and evaluate strategies for moving evidence into clinical practice. His current NIH and AHRQ funding addresses the implementation and outcomes of noninvasive ventilation in the management of patients hospitalized with exacerbations of COPD, the perioperative management of patients with obstructive sleep apnea, and the determinants of implementation effectiveness within a large quality improvement collaborative. Dr. Lindenauer has substantial mentoring and career development expertise and a growing track record of productive and successfully funded mentees.
Jamie Maguire, PhD
Dr. Maguire’s research focuses on the regulation of GABAA receptors (GABAARs), which mediate the majority of inhibitory synaptic transmission in the central nervous system. Her goal is to understand how GABAARs and therefore GABAergic inhibition, are regulated under both physiological and pathological conditions. One of the major goals of her lab is to understand the mechanisms through which stress negatively impacts health. Her research focuses on sex differences and estrous cycle changes in GABAergic inhibition, particularly related to sex specific conditions such as major depression and postpartum depression. Her laboratory has expertise in a wide variety of approaches, ranging from electrophysiology to behavior. A particular focus of the lab is the GABAergic regulation of the hypothalamic-pituitary-adrenal (HPA) axis, which mediates the body’s response to stress. Her research focuses on interventions to influence this regulatory mechanism to modulate HPA axis function for the treatment of stress-related disorders, with a focus on epilepsy and depression.
Timothy McAlindon, MD, MPH
Dr. McAlindon is a widely recognized expert in osteoarthritis. He has been supported by multiple grants including several from the National Institutes of Health. His research has been published in prestigious journals and have been influential in guiding osteoarthritis treatment. He serves as the Natalie V. Zucker and Milton O. Zucker Chair of Rheumatology at Tufts Medical Center.
Dominique Michaud, PhD
Dr. Michaud recently joined the Department of Public Health & Community Medicine at Tufts University School of Medicine. She obtained her ScD from the Harvard School of Public Health and has been prior faculty at Harvard, Imperial College London, and Brown University. Her areas of expertise include examining a wide range of risk factors for pancreatic, brain, and bladder cancers in large population cohort studies. Her current research is focused on oral health, microbiome, and human pancreatic cancer.
Marilyn Minus, PhD
Dr. Minus is an Assistant Professor in the Department of Mechanical and Industrial Engineering at Northeastern University in Boston, MA, USA. Prior to joining the faculty at Northeastern she was a Research Scientist at Georgia Institute of Technology in the School of Polymer, Textile, and Fiber Engineering.
Dr. Minus’s research interests concern the structure-property relationships in nano-composites. Dr. Minus’ research is also focused in the area of fabrication and characterization of advanced high-performance polymer nano-composites. Polymers of interest include mainly those of linear architectures and biopolymers. Her work also looks at the interfacial interaction of these polymers with carbon nano-materials to understand morphological behavior in high-performance composites.
Dr. Minus is a member of the Society of Plastic Engineers, American Chemical Society, and Materials Research Society.
Karl Munger, PhD
Dr. Munger’s research group studies the molecular mechanisms that contribute to the oncogenicity of “high-risk” human papillomaviruses (HPVs), which cause almost all cases of cervical carcinomas and a large proportion of other anogenital tract and oral cancers. While cervical cancer rates have been decreasing in the US, rates of HPV associated anal and oral cancers are on the rise, and cervical carcinomas remain a major cause of cancer death in women, worldwide. Current prophylactic vaccines do not alter disease progression in already infected individuals and since vaccination rates in the US remain low, high-risk HPV infections will remain a major cause of morbidity and mortality. He also investigates cutaneous HPVs, as well as certain animal papillomaviruses, to investigate how infections with these viruses contribute to skin carcinogenesis
Peter J. Neumann, ScD
Dr. Neumann is Director of the Center for the Evaluation of Value and Risk in Health at the Institute for Clinical Research and Health Policy Studies at Tufts Medical Center, and Professor of Medicine at Tufts University School of Medicine. His translational research focuses on the use of comparative effectiveness research and cost-effectiveness analysis in health care decision making. He brings expertise in health economics, cost-effectiveness analysis, patient preferences, and health policy. He has conducted and mentored trainees on numerous economic evaluations on a variety of topics, including interventions for Alzheimer’s disease, cancer, and cardiovascular disease. His other work and mentoring on the assessment of patient preferences has involved the measurement of health utilities and willingness to pay. Dr. Neumann has written widely on the role of clinical and economic evidence in pharmaceutical decision making.
Anastassios G. Pittas, MD
Dr. Pittas is uniquely positioned to serve as a mentor to trainees in the Tufts CTSI KL2 award, in the area of diabetes, nutrition and metabolism. He is currently the Co-Director of the Diabetes Program and the Associate Director of the Endocrinology Fellowship Program at Tufts Medical Center. From 2000 to 2008, he served as the Director of the Endocrine Pathophysiology course at Tufts University School of Medicine and he also serves as an instructor for the Study Design course at the Clinical Research Program at Tufts. Under his varied roles in the Tufts educational environment, Dr. Pittas has served as mentor for a number of post-graduate trainees and has co-authored many manuscripts in the area of diabetes, nutrition and metabolism. His mentoring has been in a wide area of clinical research, including observational studies, clinical trials and comparative effectiveness research. Three of his most recent endocrinology fellows are now Assistant Professors. His current research, supported by Federal and non-Federal sources, is focused on the role of vitamin D on cardiometabolic disease and includes two observational studies nested in two large national cohorts and two recently completed randomized trials. Dr. Pittas is currently conducting two large multi-center trials that will test the efficacy and safety of vitamin D supplementation for prevention and treatment of type 2 diabetes (www.d2dstudy.org).
Frederic Resnic, MD, MSc
Dr. Resnic is a cardiologist in Burlington, Massachusetts and is affiliated with multiple hospitals in the area, including Brigham and Women’s Hospital and Lahey Hospital and Medical Center. He received his medical degree from Icahn School of Medicine at Mount Sinai and has been in practice for more than 20 years.
Clifford Rosen, MD
Dr. Rosen is the Director of Clinical and Translational Research and a Senior Scientist at Maine Medical Center’s Research Institute. He is a Professor of Medicine at Tufts University School of Medicine.
He was the first Editor-in-Chief of the Journal of Clinical Densitometry, is the current Editor-in-Chief of The Primer in Metabolic Bone Diseases, and is the Associate Editor for New England Journal of Medicine. His publications include more than 369 peer-reviewed manuscripts, covering both clinical and basic bone biology.
Dr. Rosen has overseen numerous phase II and III clinical trials, funded both privately and through the NIH. He is a member of the FDA Advisory Panel on Endocrinologic and Metabolic Drugs and a former chairperson of that committee. He also has served on two Institute of Medicine Committees, and was Chair of the NIH Review Panel for Skeletal Biology and Bone Diseases for 2002-2004.
He is the current Chair of the Clinical Trials Review Panel for NIAMS. He was a previous member of the NIAMS Scientific Advisory Board and served as president of the American Society for Bone and Mineral Research in 2002-2003.
Dr. Rosen’s research interests include the genetic regulation of IGF-I, skeletal metabolism and stem cell fate, PTH as an anabolic therapy, and the relationship between marrow adipogenesis and osteoblastogenesis.
Mark J. Sarnak, MD
Dr. Sarnak is Director of Research in the Division of Nephrology at Tufts Medical Center and Professor of Medicine at Tufts University School of Medicine (TUSM). Over the last 13 years, Dr. Sarnak’s primary research interest has been on the evaluation of risk factors for both progression of chronic kidney disease (CKD), development of vascular disease, understanding causes of kidney disease in aging, and investigating causes of cognitive impairment in dialysis patients. He was Co-Chair and lead author of the Writing Committee on “Kidney Disease as a Risk Factor for Cardiovascular Disease” that was commissioned by the Council on Kidney Disease in Cardiovascular Disease of the American Heart Association. Dr. Sarnak was the Principal Investigator of the grant “Cystatin C and Aging Success” in the Cardiovascular Health Study which demonstrated the remarkable associations of reduced glomerular filtration rate with a broad range of adverse outcomes in the elderly and the ability of cystatin C to predict outcomes more accurately than serum creatinine. This grant has been renewed using data from the Multiethnic Study of Atherosclerosis (MESA) and the Health Aging and Body Composition Study (Health ABC) with the title “The Aging Kidney: Chronic Injury, Impaired Functions and Clinical Outcomes” which focuses on understanding the importance of entire nephron function, rather than exclusively filtration. Dr. Sarnak is also Principal Investigator on an R01 grant which evaluates cognitive impairment in dialysis patients. Dr. Sarnak has assembled a large research group including multiple close collaborators throughout the US. He has mentored many undergraduate and medical students, residents, fellows and junior faculty and was the recipient of a K24 Midcareer Investigator Award in Patient-Oriented Research which provided effort for mentoring. Several of his mentees have become patient-oriented researchers, received their own grants, and become independent investigators.
Harry P. Selker, MD, MSPH
As Dean of Tufts Clinical and Translational Science Institute (CTSI) and Principal Investigator of the Tufts Clinical and Translational Science Award (CTSA), Dr. Selker provides leadership for the programs and infrastructure that support clinical and translational research at the 12 Tufts University Schools, ten Tufts teaching hospitals, three other CTSI academic partners, and community-based and industry CTSI partners. He is also the Executive Director of the Institute for Clinical Research and Health Policy Studies at Tufts Medical Center, and Director of its Center for Cardiovascular Health Services Research.
Nationally, he is an active member of the National CTSA Consortium (on the Steering, Executive, and Strategic Goal Committees), was a founder and was second President of the Society for Clinical and Translational Science, and a founder and President of the Association for Clinical Research Training. He also served as President of the Society of General Internal Medicine for 2011-2012.
His research has long focused on the development of treatment strategies, decision aids, methods, and systems aimed at improving medical care, especially emergency and cardiac care. He is particularly known for a series of studies of the factors influencing emergency cardiac care and for development of clinical predictive instruments as decision aids that provide emergency physicians and paramedics with predictions for their patients’ likely cardiac diagnoses and outcomes for real-time use in clinical care. Concurrently, he is involved in research to advance clinical study design, data analysis, mathematical predictive modeling of medical outcomes, and comparative effectiveness research. These efforts have been continuously funded by RO1 and U awards for over 25 years.
He continues to mentor actively, currently including four fellows, three K awardees and other junior and senior faculty at Tufts and beyond. For over twenty years he was the PI on a disease-agnostic Clinical Care Research/Health Services Research T32 training grant. During this time he also founded the nation’s first MS/PhD program in clinical research at a biomedical graduate school and academic medical center.
Charles Shoemaker, PhD
Dr. Shoemaker currently leads research focused on the development of therapies for the prevention and treatment of microbial toxins and helminth parasite infections. Research applies molecular biology tools to gain understanding of host-pathogen interactions and to use the information for development of new therapeutic strategies.
Dr. Shoemaker’s lab is developing treatments for both the prevention and cure of intoxication from a number of microbial toxins, primarily bioterror threat agents such as Botulinum neurotoxins and toxins from Clostridium difficile, E. coli, anthrax and ricin. The antitoxin technology is also being adapted for the development of novel antiviral therapies. In addition, Dr. Shoemaker co-leads (with Dr. Patrick Skelly) the Molecular Helminthology Laboratory in which research is directed to the development of therapeutics and vaccines for parasitic worm infections. Research is focused on characterizing the complex host-parasite relationship in nematode and trematode diseases infecting billions of people in the developing world and causing serious economic losses in the animal industries.
Srinivas Sridhar, PhD
Dr. Sridhar is Arts and Sciences Distinguished Professor of Physics at Northeastern University, and Lecturer on Radiation Oncology, Harvard Medical School. He is the Director and Principal Investigator of several multi-M$ national programs: “Nanomedicine Science and Technology”, an IGERT (Integrative Graduate Education and Research Training) program funded by the National Cancer Institute and the National Science Foundation; “CaNCURE: Cancer Nanomedicine Coops for Undergraduate Research and Education” funded by the National Cancer Institute; and “Nanomedicine Academy” funded by the National Science Foundation. He is the founding director of the Electronic Materials Research Institute, an interdisciplinary center with research and education thrusts in nanomedicine and nanomaterials. From 2004 to 2008 he served as Vice Provost for Research at Northeastern University, overseeing the University’s research portfolio. An elected Fellow of the American Physical Society, Sridhar’s current areas of research are nanomedicine and nanophotonics. His paper on flat lens imaging published in Nature in 2003 was selected by the journal Science as among the Breakthroughs of the Year. He has published more than 200 articles on his work in nanomedicine, neurotechnology, nanomaterials, quantum chaos, superconductivity and collective excitations in materials. His research projects in nanomedicine and neurotechnology are funded by the NSF, NIH, DOD and foundations.
Cindy Thomas, PhD
Dr. Thomas is Associate Research Professor at the Brandeis University Schneider Institute for Health Policy, with a research and evaluation focus on state and national health reform, pharmacy policy and insurance benefit design. Dr. Thomas’ current work includes analyses of drug utilization and spending trends, evaluations of the impact of state coverage programs, Medicaid pharmacy coverage, and access to emerging pharmaceuticals, from the perspective of providers, beneficiaries and other stakeholders. In the area of behavioral health, her work includes adoption and impact of new treatments for substance abuse, monitoring the prescribing and use of controlled substances, and development of performance measures for medication assisted treatment of substance use disorders.
Dr. Thomas’ additional published work includes adoption of health information technology and electronic prescribing, and drug management practices in managed care organizations. Work in the area of prescription drug policy for low income and elderly populations includes pharmaceutical utilization and expenditure trends, the impact of newly introduced medications, savings from use of generic medications, plan design analyses, and other prescription drug issues, particularly in the Medicare and Medicaid population.
Dr. Thomas holds a PhD in Health Policy from Brandeis University Heller Graduate School and a Master’s Degree in Health Policy and Management from the Harvard School of Public Health. She is also a Physician’s Assistant, in the past specializing in internal medicine, trauma and emergency care in both Kaiser Health Plan and rural private practice settings.
Carole Ann Trotman, BDS, MS, MA
Dr. Trotman is a tenured Professor, Chair and Program Director of the Orthodontic Department. She is responsible for overall leadership and management of the department including curriculum development, clinical operations, student mentorship, faculty and staff performance, faculty development, and alumni relations.
Dr. Trotman received her dental degree from Dundee University, Scotland and her Orthodontic Degree and MA in Oral Biology from Columbia University, NY. She then completed a Fellowship in Craniofacial Anomalies at the Hospital for Sick Children in Toronto. Subsequently, she was appointed Assistant Professor in the Department of Orthodontics at the University of Michigan School of Dentistry. During her tenure at Michigan, she obtained an MS in Clinical Research Design and Statistical Analysis from the Horace Rackham School of Graduate Studies. Dr. Trotman then was appointed Associate Professor in the Department of Orthodontics at the University of North Carolina (UNC) School of Dentistry. Subsequently, she was promoted to Professor and served as the Interim Associate Dean for Academic Affairs and then Assistant Dean for Graduate Education at UNC. She then was appointed Professor and Associate Dean for Academic and Student Affairs at the University of Maryland School of Dentistry. Dr. Trotman was an American Council on Education Fellow, is a Diplomate of the American Board of Orthodontics, and maintains and active research program with a focus on craniofacial anomalies.
Olga Vitek, PhD
Dr. Vitek’s group develops statistical and computational methods for systems-wide molecular investigations of biological organisms. The group works with high-throughput large-scale investigations in quantitative genomics, proteomics, metabolomics and ionomics, which rely on mass spectrometry and other complementary technologies to characterize the components of the biological systems, their functional interactions, and their relevance to disease.
The research goal is to provide statistical and computational methods and open-source software for design of these experiments, and for accurate and objective interpretation of the resulting large and complex datasets. The methods build on the insight that the biological systems, and their large-scale measurements, contain redundancy. We therefore use measurements known to share sources of variation in single or multiple datasets, or discover these groups empirically from the data, to best represent their stochastic structure. The software, typically based on the environment R, introduces novel design features that ensure the scalability and the reproducibility of the results.
Chenchen Wang, MD
Dr. Wang is an Associate Professor of Medicine at Tufts University School of Medicine and the Director of the Center for Integrative Medicine Program at Tufts Medical Center in Boston. She previously completed her rheumatology and clinical epidemiology training at McGill University in 1999. Her research focuses on clinical and epidemiological studies of complementary and alternative medicine and their applications to treatments in chronic pain conditions, particularly osteoarthritis, rheumatoid arthritis, fibromyalgia, and post-traumatic stress disorder. Currently, Dr. Wang serves as Principal Investigator on several NIH-funded clinical trials evaluating Tai Chi mind-body therapies on chronic conditions and publishes extensively in this field and others.
His research has focused on evidence synthesis, comparative effectiveness research, guideline development, and performance measures through the application of decision analysis to medical issues to help patients, physicians, and policymakers choose among alternative tests, treatments or policies. Examining the comparative effectiveness of coronary revascularization decisions for the American College of Physicians and then the Agency for Health Care Policy and Research were his very first research experiences and formed the basis for his entire career, including evidence synthesis, comparative effectiveness research, and value of information based on both RCTs and observational studies. As a consequence of these experiences, he has been invited to 1) be the statistical editor for decision and cost-effectiveness analyses for the Annals of Internal Medicine, 2) participate in numerous consensus conferences, guideline development processes and appropriateness panels (WHO, IOM, NIH, CDC, ACP, ACC, AHA, AASLD, OMERACT and EULAR), 3) translate guidelines into quality improvement and performance measures, and 4) qualitative research for stakeholder preferences and values, in particular patient quality of life.